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Summary
Background: Progress in management of acute myocardial infarction (AMI) might
have changed the effect of gender on mortality.
Methods: From May 1981 to November 2002, 1984 consecutive patients with AMI
underwent emergency coronary angiography. They were divided into three groups
in chronological order: group I (1981—1988, n = 564); group II (1989—1995, n = 678);
and group III (1997—2002, n = 742). Multi-variable analysis was performed using Cox’s
proportional hazard regression, adjusting baseline clinical and angiographical vari-
ables.
Results: There were 405 women (20%). Thrombolysis was most frequently performed
in group I (50%), balloon angioplasty in group II (71%), and stent in group III (66%),
with no difference in the allocation of reperfusion therapy between men and women.
Three-year mortality was signiﬁcantly higher in women than in men in group I (27%
vs 18%, p = 0.03) and group II (23% vs 15%, p = 0.048). In group III, there was no
signiﬁcant difference in 3-year mortality (12% vs 10%, p = 0.66) between women and
men. Women were associated with higher age, more diabetes, more hypertension,
fewer current smokers, and less previous infarction than men. Multi-variable analysis
showed that sex was not an independent predictor of 3-year mortality in the three
groups.
Conclusions: Women with AMI who were treated mostly with primary intervention
using stent in the contemporary era had similar mortality to men.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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Trends in mortality of women with AMI
ntroduction
cute myocardial infarction (AMI) is a leading
ause of mortality in women as well as men in
eveloped countries. Since the introduction of
eperfusion therapy, several studies have demon-
trated beneﬁcial effects of thrombolysis [1].
rimary balloon angioplasty, as compared with
hrombolysis, has been shown to decrease mortal-
ty after AMI [2]. Outcome after AMI has further
mproved with contemporary management, includ-
ng stent implantation and ancillary medications
3]. During recent decades, many studies have
eported that women have higher mortality after
MI than men [4—7]. Recently, some studies have
eported that beneﬁts from coronary intervention
re larger in women than men, and that gender is
ot a predictor of mortality in patients undergo-
ng primary coronary intervention [8,9]. However,
o previous study compared gender difference
n mortality after AMI between the thrombolysis
ra, the balloon angioplasty era, and the stent
ra. In this study, we investigated the tempo-
al trends in mortality of women and men with
MI.
ethods
rom May 1981 to November 2002, 1984 patients
ith AMI who underwent coronary angiography
ithin 24 h after the onset of symptoms at
iroshima City Hospital, a tertiary referral insti-
ution, were prospectively registered. AMI was
iagnosed by chest pain consistent with ongoing
yocardial ischemia persisting longer than 30min
nd concomitant electrocardiographic changes.
erum creatine kinase was measured every 3 h
or at least 24 h, and peak creatine kinase value
ad to be more than twice the normal upper
imit. They were divided into three groups in
hronological order: group I (thrombolysis era:
981—1988, n = 564); group II (balloon angioplasty
ra: 1989—1995, n = 551); and group III (stent era:
997—2002, n = 869).
Emergency coronary angiography was performed
n a manner as previously reported [10]. Selective
oronary angiography was performed in multiple
rojections before the initiation of reperfusion
herapy. Immediately after diagnostic angiography,
eperfusion therapy was performed with coronary
hrombolysis or coronary intervention, if appropri-
te. Not only primary coronary intervention, but
lso coronary intervention following thrombolytic
herapy was categorized as coronary intervention.
oronary intervention was classiﬁed into con-
B
w
s
p
g233
entional balloon angioplasty and coronary stent
mplantation. The allocation of thrombolysis or
oronary intervention was not randomized and was
ased on the physician’s decision.
All coronary angiograms were reviewed by two
ngiographers without knowledge of the clini-
al variables. The perfusion status of the infarct
elated artery was determined in accordance with
he thrombolysis in myocardial infarction (TIMI)
tudy classiﬁcation [11]. An initially occluded artery
as deﬁned as TIMI-0 or TIMI-1 ﬂow before the
nitiation of reperfusion therapy. Successful reper-
usion was deﬁned as TIMI-3 ﬂow on the ﬁnal shot
f the angiography. Multi-vessel coronary disease
as deﬁned as ≥75% stenosis in one or more vessels
emote from the infarct artery. Collateral circu-
ation was considered to be present if partial or
omplete ﬁlling of the infarct artery distal to the
nfarct lesion was present.
tatistical analysis
ategorical data are reported as proportions and
ontinuous data as mean values with standard devi-
tions. Statistical analysis was performed with the
hi-square test for categorical variables. The t test
nd ANOVA were used for continuous variables.
aplan—Meier estimates were used to construct a
ong-term survival curve. Follow-up was achieved
or up to 3 years by reviewing a clinical record or
form mailed to the patients or families, deter-
ining the vital status of the patients. Differences
n 3-year mortality were assessed with the gen-
ralized Wilcoxon test. Cox proportional hazards
egression was used to obtain odds ratio (OR) and
5% conﬁdence interval (CI) for 3-year mortality.
ulti-variable analysis was performed to obtain
R and 95% CI of women for 3-year mortality,
djusting age (model 1) or age, hypertension, dia-
etes mellitus, current smoking, Killip class, time
o angiography, infarct location, initial occlusion
f the infarct artery, collateral circulation, multi-
essel disease, and ﬁnal reperfusion (model 2). We
sed the JMP statistical package (version 5.0.1 J).
signiﬁcance level of 0.05 was used and two-tailed
ests were applied.
esults
here were 405 women (20%) and 1579 men (80%).
aseline clinical and angiographic characteristics of
omen and men in group I, group II, and group III are
hown in Table 1. Thrombolysis was most frequently
erformed in group I (50%), balloon angioplasty in
roup II (71%), and stent in group III (66%). On the
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Table 1 Baseline characteristics of the study patients
Group I Group II Group III
Men Women p value Men Women p value Men Women p value
Number of patients (%) 446 (79) 118 (21) 448 (81) 103 (19) 685 (79) 184 (21)
Age (years), mean (S.D.) 59 (11) 66 (9) <0.001 61 (11) 67 (11) <0.001 62 (11) 70 (9) <0.001
Hypertension (%) 36 55 <0.001 33 50 0.003 38 54 <0.001
Diabetes mellitus (%) 19 25 0.17 21 30 0.04 26 33 0.04
Current Smoker (%) 67 30 <0.001 60 21 <0.001 58 23 <0.001
Previous infarction (%) 12 9 0.39 16 8 0.03 14 5 <0.001
Killip class 2—4 (%) 13 14 0.69 10 14 0.24 15 17 0.41
Time to angiography (h), mean (S.D.) 470 (4.7) 5.9 (4.7) 0.85 5.2 (4.7) 6.0 (5.7) 0.14 5.0 (5.2) 5.5 (5.2) 0.28
Anterior location (%) 56 50 0.24 50 50 0.93 49 49 0.89
Initial TIMI 0—1 (%) 76 78 0.69 79 76 0.41 76 72 0.28
Collateral circulation (%) 31 26 0.28 34 35 0.84 30 23 0.06
Multi-vessel disease (%) 33 44 0.02 38 38 0.92 41 39 0.57
Reperfusion therapy 0.39 0.09 0.04
Thrombolysis (%) 48 54 14 17 6 4
Balloon angioplasty (%) 39 33 71 70 18 26
Stent (%) 0 0 3 0 67 63
Bypass surgery (%) 4 2 7 5 6 3
Neither (%) 9 11 4 8 4 4
Final TIMI 3* (n) 230/430 48/116 0.02 322/416 75/98 0.85 556/649 152/179 0.43
(%) 53 41 77 77 87 85
* Patients treated with bypass surgery (n = 101) were excluded.
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Digure 1 Three-year mortality curves of group I, group
I, and group III.
nal angiography, the rate of achieving TIMI-3 ﬂow
mproved in chronological order: 51% in group I,
7% in group II, and 87% in group III (p < 0.001).
he choice of reperfusion therapy was essentially
imilar between women and men. Women were
ssociated with lower rate of achieving TIMI-3 ﬂow
n group I, but not in group II and group III.
When all patients were analyzed, women were
ssociated with signiﬁcantly higher 30-day mortal-
ty (10% vs 7%, p = 0.01) and 3-year mortality (19%
s 14%, p = 0.009). Fig. 1 shows 3-year mortality
urves of group I, group II, and group III. Mortality
fter AMI decreased signiﬁcantly in chronological
rder; 30-day mortality was 12% in group I, 8%
n group II, and 5% in group III (p < 0.001). 3-year
ortality was 20% in group I, 17% in group II, and
1% in group III (p < 0.001). If gender difference in
ortality was compared according to the reperfu-
ion therapy used, women were associated with
igher 3-year mortality after thrombolysis (25%
s 17%, p = 0.07) and balloon angioplasty (21% vs
3%, p = 0.009), but not after stent (10% vs 10%,
= 0.65).
Three-year mortality curves of women and men
n the three groups are shown in Fig. 2. In group
, 30-day mortality (19% vs 10%, p = 0.01) and
-year mortality (27% vs 18%, p = 0.03) were sig-
iﬁcantly higher in women than in men. In group
I, 30-day mortality was 11% in women and 7%
n men (p = 0.20). Three-year mortality was sig-
iﬁcantly higher in women than in men (23% vs
5%, p = 0.048). In group III, there was no signif-
cant difference in 30-day mortality (4% vs 5%,
= 0.72) and 3-year mortality (12% vs 10%, p = 0.66)
etween women and men. Multi-variable analysis
howed that sex was not an independent pre-
ictor of 3-year mortality in the three groups
Table 2).
T
3
a
cigure 2 Three-year mortality curves of women (black
ars) and men (white bars) in group I (a), in group II (b),
nd in group III (c).
iscussionhis study showed that women with AMI had higher
-year mortality than men in the thrombolysis era
nd the balloon angioplasty era. Women were asso-
iated with higher age and more co-morbid risk
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Table 2 Unadjusted and adjusted odds ratios for 3-year mortality
Unadjusted odds
ratio (95% CI)
Odds ratio adjusted
for age (95% CI)
Odds ratio adjusted for age
and other covariates (95% CI)
Group I 1.25 (1.01—1.53) 1.10 (0.88—1.34) 0.96 (0.72—1.22)
Group II 1.26 (0.99—1.58) 1.06 (0.83—1.34) 1.03 (0.78—1.34)
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yGroup III 1.06 (0.81—1.35) 0.96
CI, conﬁdence interval.
factors as compared with men. After adjustment
for these variables, gender was not an indepen-
dent predictor of 3-year mortality. This study also
showed a progressive decrease in 3-year mortality,
which was more obvious in women than in men. In
the stent era, there was no signiﬁcant difference
in 3-year mortality between women and men with
AMI.
Considerable numbers of studies have demon-
strated that mortality after AMI was higher in
women than in men. In the thrombolysis era,
both 30-day and 3-year mortality were signiﬁcantly
higher in women than in men. The rate of achieving
TIMI-3 ﬂow was signiﬁcantly lower in women than
in men. Previous reports also have reported that
women treated with thrombolytic therapy were at
greater risk of complications and women with rein-
farction following thrombolysis had more frequent
early death than men [12,13]. Another possible
explanation for the gender difference in mortality
after AMI is difference in their risk proﬁles. Consis-
tent with previous studies, women with AMI in our
study constituted a high-risk population: women
had higher age and more co-morbid risk factors.
Most previous studies have reported that, after
adjustment for age and co-morbid risk factors, gen-
der was not an independent predictor of mortality
after AMI. The third International Study of Infarct
Survival (ISIS-3) reported that more than two thirds
of the excess in mortality among women was elim-
inated by age adjustment and the remaining one
third’s excess by adjustment of other co-morbid
risk factors [14]. This study also showed that unad-
justed mortality after AMI was higher in women in
the thrombolysis era, but there was no signiﬁcant
difference in mortality after adjusting for age and
other risk factors.
In the early 1990s, several studies compared
the usefulness of primary balloon angioplasty with
thrombolysis and showed that primary balloon
angioplasty increased the rate of successful reper-
fusion and decreased mortality over thrombolysis.
In this study, the rate of achieving TIMI-3 in the
balloon angioplasty era was 77% and there was
no difference between women and men. There
was still a tendency toward higher 30-day mor-
a
m
I
w3—1.23) 0.97 (0.71—1.29)
ality in women, but the difference was narrow
nd statistically non-signiﬁcant. Although success-
ul reperfusion was obtained in more than three
uarters of the patients, the occurrence of early
ecurrent ischemia and reinfarction that abolish the
eneﬁcial effects of reperfusion therapy was con-
iderably high. It has been reported that women
uffer from such complications after plain balloon
ngioplasty more frequently than men [15]. Previ-
us studies reported that mortality was higher in
omen undergoing primary balloon angioplasty for
MI than in men [16]. In this study, the difference in
ortality gradually increased thereafter and 3-year
ortality was signiﬁcantly higher in women than in
en.
Coronary stenting has the potential to overcome
hese limitations of balloon angioplasty. It has been
eported that outcome after primary stent is favor-
ble to primary balloon angioplasty, even if the
ngiographic ﬁndings are optimal or ‘stent-like’
fter balloon angioplasty [17]. Such recent progress
n reperfusion therapy along with progress in med-
cal therapy has improved the outcome of patients
ith AMI in women as well as in men. There are
onﬂicting data on the issue of higher mortality
n women with AMI treated with primary stenting.
he Controlled Abciximab and Devices Investigation
o Lower Late Angioplasty Complications (CADIL-
AC) trial has reported higher mortality in women
ompared with men even after interventional treat-
ent for AMI [18]. However, it was a randomized
rial that consisted of selected patients. Mehilli et
l. reviewed 1937 consecutive patients with AMI
ho were mostly treated with primary coronary
ntervention using stents [8]. Primary angioplasty
as performed in 84.6% of women and 86.2% of
en. Despite their more advanced age and greater
revalence of diabetes or hypertension, women
ad similar 1-year mortality to men. Similarly,
n this study, primary coronary intervention was
erformed in 89% of women and 84% of men. Three-
ear mortality was not different between women
nd men in the stent era, despite higher age and
ore co-morbid risk factors in women than men.
t has been reported that women were associated
ith higher incidence of dissection and vascular
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ntry site complications after percutaneous trans-
uminal coronary angioplasty [15]. Use of stents
ramatically reduced dissection after percutaneous
oronary interventions and recent progress has
ermitted the use of smaller diameter catheters,
hich has reduced the incidence of vascular entry
ite complications.
Koek et al. have reported that gender differ-
nce in mortality after AMI became smaller among
atients who underwent reperfusion therapy as
ompared to those without reperfusion therapy,
ut mortality was still higher even in women who
nderwent angioplasty/thrombolysis [19]. We also
howed that women mostly treated with throm-
olysis or balloon angioplasty had higher mortality
han men. However, in the modern stent era,
he improvement in outcome was more obvious in
omen than in men and there was no signiﬁcant
ifference in 3-year mortality after AMI between
omen and men. Several studies have reported that
vidence-based therapies, including primary coro-
ary intervention, are underused in women with
MI [20,21]. It has been suggested that if women
ave access to the same quality treatment as men,
heir survival will be the same [22]. In the current
tudy, all patients with AMI eligible for reperfu-
ion therapy were encouraged to undergo coronary
ngiography. Since 1997 (group III), primary coro-
ary intervention using stents was the preferred
pproach in both men and women, and mortality
fter AMI was no longer different between men
nd women. Aggressive management with primary
ngioplasty using stents for women may eliminate
ender differences in mortality after AMI.
This is a retrospective study. However, all
onsecutive patients with AMI who underwent coro-
ary angiography were prospectively included in a
ingle-center registry. The allocation of reperfusion
herapy was based on the physician’s decision. But
he choice of reperfusion therapy was essentially
dentical between women and men without sex-
ased difference in the use of primary coronary
ntervention. Recent progress in medical man-
gement along with reperfusion therapy, such as
tatins, angiotensin-converting enzyme inhibitors,
ngiotensin receptor blockers, and beta-blockers,
ight have inﬂuenced the change in gender dif-
erence in mortality after AMI. However, our study
id not include these data on ancillary medica-
ions. Prevalence of women was relatively smaller
n this study (20%) as compared with previous stud-
es from tertiary referral institutions (22—32%),
uggesting selection bias of this study. Indeed, this
tudy included only those patients who underwent
oronary angiography within 24 h after the onset
f AMI. However, it is still noteworthy that the
[
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revalence of women and the gender difference in
ge were consistent throughout the study period.
herefore, selection bias seemed not to be the rea-
on why mortality of women after AMI in the stent
ra became as low as that of men. Small sample
ize is another limitation of this study. A large-scale
ationwide registry should be warranted to assess
ender difference in mortality after AMI in the con-
emporary stent era in Japan.
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